Wellesley hills
WELLESLEY HILLS, Massachusetts, November 29, 2011 -
Joseph F.
WELLESLEY HILLS, Massachusetts, November 17, 2011 -
S1P1 Lead Compounds will be Offered for Sale at a December 8, 2011 Sealed Bid Sale.
WELLESLEY HILLS, Massachusetts, November 9, 2011 -
Joseph F.
WELLESLEY HILLS, Massachusetts, November 1, 2011 -
Joseph F.
WELLESLEY HILLS, Massachusetts, November 1, 2011 -
??
In the news release, Mechanology, Inc.'s Steam Turbines, Business Offered for Sale at a Sealed Bid Sale on November 18, 2011, are Suited for Applications in Power Recovery and Power Generation Packages, issued Nov.
More News
- Back-Up Compounds and S1P1 Lead Compounds, Assets Generated by Epix Pharmaceuticals, Inc. and Amgen, Will Be Offered for Sale at a December 8, 2011 Sealed Bid Sale
- Contractual Agreements Revealed for S1P1 Lead Compounds, AMG 369 and AMG 277, Offered for Sale at a December 8, 2011 Sealed Bid Sale
- S1P1 Agonists are Currently Indicated For Treatment of Multiple Sclerosis
- S1P1 Lead Compounds, AMG 369 and AMG 277, Will Be Offered for Sale at a December 8, 2011 Sealed Bid Sale
- S1P1 Program Assets Generated by Epix Pharmaceuticals, Inc. and Amgen Will Be Offered for Sale at a December 8, 2011 Sealed Bid Sale
- Mechanology, Inc.’s Steam Turbines, Business Offered for Sale at a Sealed Bid Sale on November 18, 2011, Are Suited for Applications in Power Recovery and Power Generation Packages
- Mechanology, Inc. Offers Its Steam Turbine Business for Sale at a Sealed Bid Sale on November 18, 2011
- NMT Medical, Inc. to Sell BioTREK Technology Platform at Its Sealed Bid Sale on Friday, June 10, 2011 at Twelve O'Clock Noon
- NMT Medical, Inc. Adds Intellectual Property to Its Sealed Bid Sale of Friday, June 10, 2011 at Twelve O'Clock Noon
- NMT Medical, Inc. Sealed Bid Sale of its Intellectual Property to Take Place Friday, June 10, 2011 at Twelve O'Clock Noon
- NMT Medical, Inc. Assigned All Its Assets to Joseph F. Finn, Jr., C.P.A. of the Firm Finn, Warnke & Gayton, LLP on April 20, 2011
- Source Precision Medicine, Inc., d/b/a Source MDx Announces Source Laboratory Information Management Systems (LIMS), Source Dynamics and Source Primer/Probe Database Will Be Offered for Sale on April 29, 2011
- Source Precision Medicine, Inc. d/b/a Source MDx Announces 16 Molecular Diagnostic Development Programs Will Be Offered for Sale on April 29, 2011
- Source Precision Medicine, Inc. d/b/a Source MDx Announces Foundational Patents Will Be Offered for Sale on April 29, 2011
- Source Precision Medicine, Inc., dba SourceMDx Assigns All Its Assets to Joseph F. Finn, Jr., C.P.A. of the firm of Finn, Warnke & Gayton, LLP
- NoblePeak Vision Corp. Offers Patented Technology to Integrate Germanium Photodetectors with Silicon Circuits at the November 5, 2010 Sealed Bid Sale
- NoblePeak Vision Corp. Offers Patented Technology to Integrate Germanium Photodetectors With Silicon Circuits at the November 5, 2010 Sealed Bid Sale
- NoblePeak Vision Corp. Assigns All Its Assets to Joseph F. Finn, Jr., C.P.A. for the Benefit of Its Creditors
- Epix Pharmaceuticals, Inc. Announces a Change in the May 28, 2010 Auction Sale of Epix Imaging Agents to June 22, 2010
- Epix Pharmaceuticals, Inc. Announces Additional Information Concerning the May 28, 2010 Auction Sale of EP-3600 MRI Imaging Agent
- Epix Pharmaceuticals, Inc. Announces Additional Information Concerning the May 28, 2010 Auction Sale of EP-2104R MRI Imaging Agent
- Epix Pharmaceuticals, Inc. Announces the May 28, 2010 Auction Sale of EP-3600 MRI Imaging Agent
- Epix Pharmaceuticals, Inc. Announces the May 28, 2010 Auction Sale of EP-2104R MRI Imaging Agent
- Epix Pharmaceuticals, Inc. Announces the May 28, 2010 Auction Sale of MS-325 MRI Imaging Agent
- Epix Pharmaceuticals, Inc. Announces the May 28, 2010 Auction Sale of Its MRI Imaging Intellectual Properties
- Finn, Warnke & Gayton Announces A New Service For Biotechnology Firms - A Platform To Sell Intellectual Property
- Joseph F. Finn, Jr., Assignee for the Benefit of Creditors of EPIX Pharmaceuticals, Inc., Releases Statement Regarding Liquidation Process
- EPIX Pharmaceuticals Announces FDA Approval of a Physician-Sponsored IND for Fourth 6-month Open Label Extension of PRX-03140 for Alzheimer’s Disease Patient
- Epix Pharmaceuticals, Inc. Announces a Successful Auction Sale of Five Drug Program Intellectual Properties on September 30, 2009
- EPIX Pharmaceuticals, Inc. Announces the P2Y2 Gastrointestinal Early Development Candidate Program Will Be Part of the Intellectual Property Offered For Sale at the September 30, 2009 Auction
- EPIX Pharmaceuticals, Inc. Announces the PRX-00023 Therapeutics CNS Program in Phase 2b/3 Will Be Part of the Intellectual Property Offered for Sale at the September 30, 2009 Auction
- Epix Pharmaceuticals, Inc. Announces the PRX-08066 Therapeutics Program in Phase 2 for Respiratory Indication Will Be Part of The Intellectual Property Offered for Sale at the September 30, 2009 Auction
- Epix Pharmaceuticals, Inc. Announces PRX-07034 Therapeutics - CNS Phase 2 Will be Part of the Intellectual Property Offered for Sale at the September 30, 2009 Auction
- EPIX Pharmaceuticals, Inc. Announces August 25, 2009 for the Auction Sale of Equipment and September 30, 2009 for the Auction Sale of the Intellectual Property
- EPIX Pharmaceuticals, Inc. Assigns all Its Assets to Joseph F. Finn, Jr., C.P.A. for the Benefit of Its Creditors
